Biote Corp. Reports Q3 2026 Financial Results Amid Post-Recall Recovery
Biote Corp. (BTMD) reported third-quarter revenue of $43.3 million, a 9.6% decrease compared to the prior year. The decline was primarily driven by a 15.1% drop in procedure revenue, which management attributed to the lingering effects of a voluntary product recall in January 2026 that impacted clinic starts and patient attrition. Despite the top-line contraction, the company saw 7.3% growth in its dietary supplements segment due to e-commerce expansion. Gross margins fell to 67.7% as the company relied on lower-margin third-party pellets during the recall period, though management noted a sequential improvement as internal manufacturing at the Asteria Health facility resumed. Net income dropped significantly to $600,000 from $9.2 million in the prior year's third quarter. While CEO Bob Peterson admitted that the return to growth is progressing slower than anticipated, the company maintained full-year revenue guidance above $175 million and adjusted EBITDA guidance above $25 million.
Topics: E-commerce growth Financial guidance Gross margin compression Product recall impact Revenue decline